News
Objective To compare individually tailored, based on trimestrial biological parameter monitoring, to fixed-schedule rituximab reinfusion for remission maintenance of antineutrophil cytoplasm antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback